11:15 IST
BSE
Other Announcement
Aurobindo Pharma Other Announcement
Aurobindo Pharma dispatched letters to shareholders without registered email IDs. These letters provide a web link to the Integrated Annual Report 2025-26.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd news stories on ALFA NewsRead the news →- Share price
- ₹1,680.80
- Market cap
- ₹97,621 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.8×Sector 47.4×
- Promoter holding
- 51.88%+0.06% QoQ
- FII holding
- 16.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Merger & Restructuring 17Regulatory Approval 9Business Update 8Management Change 4Earnings Call 4Other Announcement 3Financial Results 3Board Meeting Outcome 2Board Meeting Date 2Annual General Meeting 2Results Update 1Production Started 1Product Launch 1Legal & Regulatory 1Debt & Borrowing 1Capacity Expansion 1Annual Report 1Adverse Business Impact 1Acquisition 1
Time
3 announcements with these filters
20:53 IST
BSE
Other Announcement
Aurobindo Pharma Other Announcement
Aurobindo Pharma appointed M/s. RPR & Associates as Secretarial Auditor for five years following M/s. MRR & Associates' resignation. The transition is due to proprietor health issues.
- Execution
- 5 years
16:02 IST
NSE
Other Announcement
Aurobindo Pharma Other Announcement
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, announced positive Phase 3 results for its Omalizumab biosimilar (BP11). The study met all primary endpoints for efficacy and safety, showing equivalence to Xolair. The company plans to file for EMA and FDA regulatory approvals by the end of Q2 2026.
- Execution
- Q2 2026